2_Company News_News_Shanghai Kechow Pharma, Inc.

中文

News

Location：Home/News/Company News

Company News

KeChow Pharma Awarded “2023 Zhangjiang Life Science Industry New Prominent”
2023-09-26
On the afternoon of September 25, 2023, Zhangjiang Life Science International Innovation Summit took
KeChow Pharma Presents Crucial Phase II Study Results on Tunlametinib for Advanced NRAS-Mutant Melanoma at 2023 ASCO Annual Meeting
2023-06-07
KeChow Pharma announced the release of efficacy and safety data for its MEK inhibitor, Tunlametinib,
CSCO 2023: Evidence Level for MEK Inhibitor Tunlametinib Capsules Elevated to Second Line-Level 1
2023-04-24
The 2023 CSCO Guidelines Conference, co-hosted by the Chinese Society of Clinical Oncology and the B
CDE Approves KeChow Pharma’s Registration Clinical Study of Tunlametinib Capsules Combined with Vemurafenib for BRAF V600E-Mutant mCRC
2023-04-05
On April 4, 2023, the Center for Drug Evaluation of the National Medical Products Administration app
KeChow Pharma’s New Drug Application for Tunlametinib Capsules for Advanced NRAS-Mutant Melanoma Accepted by NMPA
2023-02-13
On February 13, 2023, Beijing time, the National Medical Products Administration (NMPA) accepted the
CDE Approves Phase II Registration Clinical Study of KeChow Pharma’s MEK Inhibitor Tunlametinib Capsules Combined with Vemurafenib for Treating BRAF V600E-Mutant NSCLC
2023-01-08
KeChow Pharma’s independently developed MEK inhibitor, Tunlametinib (HL-085), in combination with Ve

<
1
2
3
4
>